DB
SOPH icon

Dmitry Balyasny’s SOPHiA GENETICS SOPH Stock Holding History

Dmitry Balyasny’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-48,277
Closed -$123K – 2871
2023
Q3 		$123K Sell
48,277
-54,730
-53% -$174K ﹤0.01% 2101
2023
Q2 		$461K Buy
+103,007
New +$466K ﹤0.01% 1876

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $369M AUM 45.79% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Dmitry Balyasny's SOPH Position: Q4 2023 in Review

Dmitry Balyasny sold out of SOPHiA GENETICS (SOPH) in Q4 2023, closing a stake of 48,277 shares — an estimated $123K sold.

Dmitry Balyasny first reported a position in SOPH in Q2 2023 and held it in 2 quarters. The position peaked at $461K in Q2 2023. 36 funds tracked by Wall St. Rank hold SOPH as of Q4 2023.

  • Dmitry Balyasny reported no remaining SOPHiA GENETICS position as of Q4 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 48,277 SOPHiA GENETICS shares in Q4 2023, an estimated $123K.
  • Dmitry Balyasny first reported a position in SOPHiA GENETICS in Q2 2023 and held it in 2 quarters.
  • Dmitry Balyasny's SOPHiA GENETICS position peaked at $461K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.